ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
16MAY, 2023
Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced a significant collaboration with Ionis Pharmaceuticals, Inc. to jointly develop an innovative antisense oligonucleotide (ASO) therapy targeting a rare and severe chronic kidney disease characterized by unmet medical needs. This partnership combines Chinook's expertise in precision medicine and nephrology with Ionis' extensive knowledge in RNA-targeted therapeutics.
The collaboration aims to leverage the power of ASO technology to address crucial genetic and molecular drivers of the kidney disease. Chinook's dedication to advancing precision medicine for kidney disorders aligns perfectly with Ionis' RNA-focused therapeutic approach.
Chinook's Chief Scientific Officer, Dr. Andrew King, expressed enthusiasm for the collaboration, highlighting how ASO therapy can help target key genetic factors and expand their pipeline of precision medicines for severe chronic kidney diseases. The ultimate goal is to reduce the dependence on dialysis and transplants for individuals suffering from kidney disease.
As part of the agreement, Chinook will provide an upfront payment to Ionis, along with potential payments linked to development milestones, regulatory achievements, and future royalties. The partnership's dynamics involve Ionis handling toxicology studies necessary for Investigational New Drug (IND) applications, while Chinook will drive clinical development and eventual commercialization.Antisense technology, employed in the ASO therapy, has a specialized mechanism to precisely target and degrade specific mRNA molecules. This approach reduces the production of disease-causing proteins, offering a potential treatment avenue for conditions resulting from both protein excess and deficiency.
Chinook Therapeutics, Inc. is a forward-looking biopharmaceutical company dedicated to developing precision medicines for kidney diseases. Their ongoing projects focus on rare and severe chronic kidney disorders, with their lead program centered on atrasentan, a phase 3 endothelin receptor antagonist. Additionally, they are actively exploring other therapeutic candidates based on their comprehensive understanding of kidney disease pathways.While looking ahead, Chinook maintains a cautious approach to forward-looking statements. They acknowledge the inherent risks and uncertainties in drug development, regulatory processes, competitive landscapes, and economic conditions. Their commitment to delivering on their mission, coupled with their appreciation of potential challenges, underpins their dedication to improving outcomes for those affected by kidney diseases.